Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 11/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2684534 | 1.00 | PRCP (0.48) | PRCPHCRTR1HCRTR2NR1I2ABCB11 | |
| SCHEMBL5991412 | 0.90 | PRCP (0.48) | PRCPHCRTR1HCRTR2NR1I2ABCB11 | |
| SCHEMBL15848392 | 0.88 | PRCP (0.54) | PRCPHCRTR1HCRTR2NR1I2ABCB11 | |
| SCHEMBL15848394 | 0.88 | PRCP (0.54) | PRCPHCRTR1HCRTR2NR1I2ABCB11 | |
| SCHEMBL2686003 | 0.83 | CYP3A4 (0.55) | PRCPHCRTR1HCRTR2NR1I2ABCB11 | |
| SCHEMBL2685422 | 0.83 | PRCP (0.59) | PRCPHCRTR1HCRTR2NR1I2ABCB11 | |
| SCHEMBL5992658 | 0.78 | HPGDS (0.49) | PRCPHCRTR1HCRTR2NR1I2ABCB11 | |
| SCHEMBL3343952 | 0.78 | PRCP (0.61) | PRCPHCRTR1HCRTR2NR1I2ABCB11 | |
| SCHEMBL15854374 | 0.75 | PRCP (0.51) | PRCPHCRTR1HCRTR2NR1I2ABCB11 | |
| SCHEMBL2788881 | 0.75 | PRCP (0.57) | PRCPHCRTR1HCRTR2NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155382-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20120115918-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115918-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | PRCP 816/4885HCRTR1 4113/4885HCRTR2 4609/4885 |
| US-20140155382-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | PRCP 816/4885HCRTR1 4113/4885HCRTR2 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.